Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (512 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: T Lymphocyte Subsets; T-Lymphocyte Subset; Subsets, T-Lymphocyte; Subset, T-Lymphocyte; T Lymphocyte Subset; T-Cell Subset; Subsets, T-Cell; Subset, T-Cell.
Where it fits in the MeSH classification
- Broader topics
- Lymphocyte Subsets; T-Lymphocytes
- Narrower topics
- Intraepithelial Lymphocytes; Mucosal-Associated Invariant T Cells; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Memory T Cells
- See also
- CD4-CD8 Ratio
Research landscape
PubMed indexes 140,087 records tagged with the MeSH heading “T-Lymphocyte Subsets” (counts retrieved 2026-10-31). 24,334 of them (17.4%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 45,341 records.
Reviews account for 18,975 records (13.5%) and meta-analyses for 157. Randomized controlled trials number 1,275 (0.9%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 35,996 |
| 2000-2009 | 34,416 |
| 2010-2019 | 45,341 |
| 2020 onward | 24,334 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 18,975 | 13.5% |
| Meta-analyses | 157 | 0.1% |
| Randomized controlled trials | 1,275 | 0.9% |
Method: PubMed query "T-Lymphocyte Subsets"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in anatomy and physiology
Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy | 2026 | Research article Design not recorded in structured metadata | 5 | cc by PMID 42584417 · DOI · PMC13521516 |
| Regulatory T cells in cancer and inflammation | 2026 | Review article Design not recorded in structured metadata | 5 | cc by PMID 42225638 · DOI · PMC13226692 |
| Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma | 2026 | Research article Design not recorded in structured metadata | 4 | cc by PMID 42192147 · DOI · PMC13389491 |
Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Regulatory T cell (Treg) therapy is an emerging platform for controlling immune overactivation.
- Closing excerpt
- Together, these results illustrate a safe and effective cell-engineering solution for overcoming Tregs' dependency on exogenous IL-2, thereby achieving superior therapeutic efficacy.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (158 words)
Regulatory T cell (Treg) therapy is an emerging platform for controlling immune overactivation. Persistence of infused Tregs is limited by insufficient IL-2, which is essential for Treg survival and function. IL-2 activates many immune cells, imposing a challenge for the selective provision of IL-2 to infused Tregs. In this study, we found that infusions of orthogonal (ortho) IL-2 failed to enhance Tregs expressing a corresponding orthoIL-2 receptor (IL-2R) in a mouse model of autoimmune diabetes. Engineering Tregs with an orthoIL-2 tethered to its receptor achieved selective autocrine signaling; increased CD25, CTLA-4, and Foxp3 expression; supported Treg persistence without exogenous IL-2 in vivo; and improved the efficacy of Treg prevention of autoimmune diabetes. Inserting the tethered orthoIL-2 construct into the Foxp3 locus enabled Treg-specific self-reinforced expression through the activation of the Foxp3 locus by increased IL-2 signaling. Together, these results illustrate a safe and effective cell-engineering solution for overcoming Tregs' dependency on exogenous IL-2, thereby achieving superior therapeutic efficacy.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42584417 · DOI · PMC13521516
Regulatory T cells in cancer and inflammation [2]
Abstract reading summary — source excerpts
- Opening excerpt
- As immunoregulatory cells, regulatory T cells (Tregs) play pivotal roles in maintaining immune tolerance and preventing autoimmunity.
- Closing excerpt
- Overall, this review greatly advances our understanding of the roles of Tregs in cancer and inflammation and helps inform the development of more precise and effective therapeutic strategies.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (205 words)
As immunoregulatory cells, regulatory T cells (Tregs) play pivotal roles in maintaining immune tolerance and preventing autoimmunity. However, Tregs exhibit distinct functions across different diseases. In cancer, Tregs are most likely to suppress antitumor immune responses and promote tumor immune evasion, whereas in inflammatory diseases, functionally competent Tregs mitigate excessive immune activation and facilitate tissue repair. Notably, dysfunctional Tregs lead to persistent inflammation and progression to chronic disease. Therefore, targeting Tregs has emerged as an attractive immunotherapeutic strategy for both cancer and inflammatory disorders. Recent studies have shown that Tregs exhibit instability and plasticity under specific conditions, allowing them to shift between functional and dysfunctional states. A comprehensive understanding of the dynamic changes in Tregs and their regulatory mechanisms in diverse pathological contexts is highly important. In this review, we summarize the dual roles of Tregs in cancer and various inflammatory diseases. We explore the signaling pathways and molecular mechanisms underlying their biological characteristics, with a particular focus on how microenvironmental cues shape Treg behavior. Additionally, we discuss recent advances in Treg-targeted therapies in these disease contexts. Overall, this review greatly advances our understanding of the roles of Tregs in cancer and inflammation and helps inform the development of more precise and effective therapeutic strategies.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42225638 · DOI · PMC13226692
Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Small extracellular vesicles (sEVs) orchestrate cell-cell communication, but the role of sEV signaling via mitochondria in perpetuating asthmatic airway inflammation is unknown.
- Closing excerpt
- Our studies indicate a previously unrecognized role for mitochondrial fission and sEV- mitochondria-mediated signaling in dysregulated T cell activation, Th polarization, and pathology in asthma.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (149 words)
Small extracellular vesicles (sEVs) orchestrate cell-cell communication, but the role of sEV signaling via mitochondria in perpetuating asthmatic airway inflammation is unknown. Myeloid-derived regulatory cells (MDRCs) control CD4+ T cell responses in asthma. We demonstrate that airway MDRC-derived sEVs from asthmatics mediate T cell receptor engagement and transfer of mitochondria that induce antigen-specific activation and polarization of Th17 and Th2 cells. sEV-dependent T cell activation and Th polarization were mediated by mitochondrial oxidant-dependent NF-κB signaling, which, when blocked, mitigated CD4+ T cell activation. Mitochondrial fission regulator, DRP-1, promoted mitochondrial packaging within MDRC-sEVs. Internalized sEVs co-localized with the polarized cytoskeleton and mitochondrial networks in recipient T cells. Intranasal transfer of mitochondria packaged sEVs enhanced allergic airway inflammation and Th polarization in a murine asthma model. Our studies indicate a previously unrecognized role for mitochondrial fission and sEV- mitochondria-mediated signaling in dysregulated T cell activation, Th polarization, and pathology in asthma.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42192147 · DOI · PMC13389491
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis [4]
- Research article Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis [5]
- Research article Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis [6]
- Research article Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential [7]
- Research article Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis [8]
- Research article Guidelines for T cell nomenclature [9]
References
- Indart AC, Lyu H, Nguyen VQ, Rosenthal W, Palvai JR, Jang SS, et al.. Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy. . 2026. PMID 42584417 · DOI · PMC13521516
- Yang H, Zhang H, Xia N, Cheng X. Regulatory T cells in cancer and inflammation. . 2026. PMID 42225638 · DOI · PMC13226692
- Hough KP, Trevor JL, Ahmad S, Wang Y, Chacko BK, Goliwas KF, et al.. Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma. . 2026. PMID 42192147 · DOI · PMC13389491
- Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015. PMID 26462617 · DOI · PMC4604472
- Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, et al.. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014. PMID 24504370 · DOI · PMC3960618
- Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al.. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis. Cytometry A. 2020. PMID 32542842 · DOI · PMC7323417
- Wang L, Liang Y, Zhao C, Ma P, Zeng S, Ju D, et al.. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduct Target Ther. 2025. PMID 41087343 · DOI · PMC12521743
- Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH, et al.. Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res. 2016. PMID 27777959 · DOI · PMC5061980
- Masopust D, Awasthi A, Bosselut R, Brooks DG, Buggert M, Chamoto K, et al.. Guidelines for T cell nomenclature. Nat Rev Immunol. 2026. PMID 41254224 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.